In 2007 the pharmaceutical company [[Gtx inc|GTx, Inc]] was conducting two different phase 3 [[clinical trial]]s; First, a pivotal Phase clinical trial for the treatment of serious side effects of [[androgen deprivation therapy]] (ADT) (especially vertebral/spine fractures and [[hot flashes]], lipid profile, and [[gynecomastia]]) for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade [[prostatic intraepithelial neoplasia]], or PIN. Results of these trials are expected by first quarter of 2008<ref>{{cite press release

 
An NDA for the first application (relief of prostate cancer ADT side effects) was submitted in Feb 2009,<ref>{{cite press release
